DK263889A - Substituerede 4-(quinolin-2-yl-methoxy)-phenyl-eddikesyre-derivater, deres fremstilling og anvendelse - Google Patents

Substituerede 4-(quinolin-2-yl-methoxy)-phenyl-eddikesyre-derivater, deres fremstilling og anvendelse Download PDF

Info

Publication number
DK263889A
DK263889A DK263889A DK263889A DK263889A DK 263889 A DK263889 A DK 263889A DK 263889 A DK263889 A DK 263889A DK 263889 A DK263889 A DK 263889A DK 263889 A DK263889 A DK 263889A
Authority
DK
Denmark
Prior art keywords
substituted
acid derivatives
quinolin
methoxy
phenyl
Prior art date
Application number
DK263889A
Other languages
English (en)
Other versions
DK263889D0 (da
DK169544B1 (da
Inventor
Klaus Mohrs
Siegfried Raddatz
Elisabeth Perzborn
Romanis Fruchtmann
Christian Kohlsdorfer
Pia Theisen
Rainer Mueller-Peddinghaus
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DK263889D0 publication Critical patent/DK263889D0/da
Publication of DK263889A publication Critical patent/DK263889A/da
Application granted granted Critical
Publication of DK169544B1 publication Critical patent/DK169544B1/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK263889A 1988-05-31 1989-05-30 Substituerede 4-(quinolin-2-yl-methoxy)-phenyl-eddikesyre-derivater, fremgangsmåde til deres fremstilling, lægemidler med indhold deraf og deres anvendelse til fremstilling af lægemidler DK169544B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3818443 1988-05-31
DE3818443 1988-05-31
DE3900261A DE3900261A1 (de) 1988-05-31 1989-01-06 Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
DE3900261 1989-01-06

Publications (3)

Publication Number Publication Date
DK263889D0 DK263889D0 (da) 1989-05-30
DK263889A true DK263889A (da) 1989-12-01
DK169544B1 DK169544B1 (da) 1994-11-28

Family

ID=25868621

Family Applications (1)

Application Number Title Priority Date Filing Date
DK263889A DK169544B1 (da) 1988-05-31 1989-05-30 Substituerede 4-(quinolin-2-yl-methoxy)-phenyl-eddikesyre-derivater, fremgangsmåde til deres fremstilling, lægemidler med indhold deraf og deres anvendelse til fremstilling af lægemidler

Country Status (20)

Country Link
US (1) US4970215A (da)
EP (1) EP0344519B1 (da)
JP (2) JP2693576B2 (da)
KR (1) KR0131202B1 (da)
CN (1) CN1030251C (da)
AT (1) ATE88183T1 (da)
AU (1) AU616269B2 (da)
CA (1) CA1333802C (da)
DE (2) DE3900261A1 (da)
DK (1) DK169544B1 (da)
ES (1) ES2053864T3 (da)
FI (1) FI91635C (da)
HK (1) HK38895A (da)
HU (2) HU207719B (da)
IE (1) IE61922B1 (da)
IL (1) IL90435A (da)
NO (1) NO174889C (da)
NZ (1) NZ229310A (da)
PT (1) PT90675B (da)
SG (1) SG12795G (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232916A (en) * 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5194438A (en) * 1988-07-15 1993-03-16 Basf Aktiengesellschaft α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods
DE3927931A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
DE3927930A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate
US5254581A (en) * 1990-06-21 1993-10-19 Imperial Chemical Industries Plc Pyran derivatives and their use as inhibitors of 5-lipoxygenase
US5221678A (en) * 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5187180A (en) * 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
DE4139751A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate
US5304563A (en) * 1991-02-22 1994-04-19 Bayer Aktiengesellschaft 2-substituted quinolines, and their use in medicaments
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4226649A1 (de) * 1992-08-12 1994-02-17 Bayer Ag Neue isobutylsubstituierte Methansulfonyl-chinolylmethoxyphenyl-cycloalkylessigsäureaminole
DE4112533A1 (de) * 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
US5391555A (en) * 1991-11-12 1995-02-21 Miles Inc. Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors
DE4139750A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe
DE4139749A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenyl-essigsaeureamide
DE4142190A1 (de) * 1991-12-20 1993-06-24 Bayer Ag Verfahren zur herstellung von optisch aktiven (alpha)-hydroxycarbonsaeuren
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
DE4219765A1 (de) * 1992-06-17 1993-12-23 Bayer Ag Substituierte (Benzothiazolyl- und Chinoxalyl-methoxy)phenylessigsäurederivate
DE4226519A1 (de) * 1992-08-11 1994-02-17 Bayer Ag 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
US5358955A (en) * 1992-10-30 1994-10-25 Abbott Laboratories Aryl and heteroarylmethoxyphenyl inhibitors of leukotriene biosynthesis
ES2061406B1 (es) * 1993-05-07 1995-06-01 Uriach & Cia Sa J Nuevos derivados de la 2-(quinolina) con actividad farmacologica.
US5512581A (en) * 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
ES2103180B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Fenilacetamidas con accion antagonista de los leucotrienos.
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
DE19536378A1 (de) * 1995-09-29 1997-04-03 Bayer Ag Heterocyclische Aryl-, Alkyl- und Cycloalkylessigsäureamide
US5668146A (en) * 1995-10-03 1997-09-16 Abbott Laboratories Symmetrical bis-heteroarylmethoxyphenyliminoxyalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5795900A (en) * 1995-10-03 1998-08-18 Abbott Laboratories Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5714488A (en) * 1995-10-03 1998-02-03 Abbott Laboratories Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5691351A (en) * 1996-02-06 1997-11-25 Abbott Laboratories Bis-(Heteroarylmethoxyphenyl)cycloalkyl carboxylates as inhibitors of leukotriene biosynthesis
US6774236B1 (en) 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
DE19613549A1 (de) * 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
DE19615262A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
DE19615263A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
US5668150A (en) * 1996-07-26 1997-09-16 Abbott Laboratories Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5783586A (en) * 1996-10-01 1998-07-21 Abbott Laboratories Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of leukotriene biosynthesis
GB2356138A (en) * 1999-11-15 2001-05-16 Bayer Ag Use of substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20050272051A1 (en) * 2003-09-17 2005-12-08 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US20060257481A1 (en) * 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
US10080748B2 (en) 2014-02-04 2018-09-25 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
TW202128637A (zh) * 2019-10-09 2021-08-01 美商百歐克斯製藥公司 口服補體因子d抑制劑
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO174506B (no) * 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
IE861607L (en) * 1985-06-18 1986-12-18 Bunce Roger A 2-substituted quinolines
DE3814504A1 (de) * 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3927931A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
US5035502A (en) * 1989-08-28 1991-07-30 Stokes William T Transparent calculator for overhead projection

Also Published As

Publication number Publication date
FI91635B (fi) 1994-04-15
DE3900261A1 (de) 1989-12-07
IE61922B1 (en) 1994-11-30
HK38895A (en) 1995-03-24
JPH0219359A (ja) 1990-01-23
SG12795G (en) 1995-06-16
ATE88183T1 (de) 1993-04-15
FI892603A0 (fi) 1989-05-29
EP0344519A1 (de) 1989-12-06
AU3527089A (en) 1989-12-07
CN1030251C (zh) 1995-11-15
HU207719B (en) 1993-05-28
US4970215A (en) 1990-11-13
FI892603A (fi) 1989-12-01
PT90675B (pt) 1994-10-31
HU211570A9 (en) 1995-12-28
NO174889C (no) 1994-07-27
NZ229310A (en) 1991-10-25
NO891962D0 (no) 1989-05-16
JPH1053577A (ja) 1998-02-24
JP3076003B2 (ja) 2000-08-14
KR0131202B1 (ko) 1998-04-17
HUT50780A (en) 1990-03-28
DK263889D0 (da) 1989-05-30
CA1333802C (en) 1995-01-03
FI91635C (fi) 1994-07-25
NO174889B (no) 1994-04-18
ES2053864T3 (es) 1994-08-01
EP0344519B1 (de) 1993-04-14
PT90675A (pt) 1989-11-30
CN1038641A (zh) 1990-01-10
AU616269B2 (en) 1991-10-24
KR900018034A (ko) 1990-12-20
DE58904042D1 (en) 1993-05-19
IL90435A0 (en) 1990-01-18
JP2693576B2 (ja) 1997-12-24
IE891784L (en) 1989-11-30
IL90435A (en) 1993-02-21
DK169544B1 (da) 1994-11-28
NO891962L (no) 1989-12-01

Similar Documents

Publication Publication Date Title
DK263889A (da) Substituerede 4-(quinolin-2-yl-methoxy)-phenyl-eddikesyre-derivater, deres fremstilling og anvendelse
DK208789A (da) Substituerede 4-(quinolin-2-yl-methoxy)-phenyleddikesyrer og estere deraf, deres fremstilling og anvendelse
NO892083D0 (no) Fremgangsmaate for fremstilling av arylmetylenyl-derivaterav tiazolidinoner, imidazolidinoner og oksazolidinoner.
NO892745D0 (no) Aminoalkylaminokarbonylaminodiolaminosyrederivater og fremgangsmaate for deres fremstilling.
DK399789D0 (da) Annellerede tetrahydropyridineddikesyrederivater, deres fremstilling og anvendelse
NL970029I1 (nl) Benzimidazoolderivaten, bereiding en therapeutische toepassing.
FI972684A (fi) Piperidiinietikkahappojohdannaisia, joita voidaan käyttää fibrinogeeniantagonisteina
DK451588A (da) Heterocycliske forbindelser, deres fremstilling og laegemidler indeholdende forbindelserne
NO951147D0 (no) Substituerte heterocykliske karboksylsyreamidestere, deres fremstilling og deres anvendelse som legemiddel
NO951811D0 (no) Kinolin- og benzimidazolderivater, deres fremstilling og anvendelse
NO894592L (no) Pyrrolidon-2-karboksylsyre-derivater med psykotropisk virkning.
FI890864A0 (fi) Anvaendning av 1,4-dihydropyridinderivat.
NO924516D0 (no) Isoxazolylimidazolderivater, fremgangsmaater for fremstilling av disse, og deres anvendelse i legemidler
NO923455D0 (no) Indolsulfonamidsubstituert dihydropyridin, fremgangsmaate for fremstilling og anvendelse i legemidler
NO901732L (no) Fremgangsmaate for fremstilling av 4-alkoksyalkyl-4-aminofenylpiperidiner og derivater derav.
NO891045D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinolin-2,5-dion-derivater.
NO911580L (no) 2-aminokarboksylsyrer og deres derivater, fremgangsmaate for fremstilling av disse og deres anvendelse som medikamenter.
DK721088A (da) 3-phenoxy-phenyleddikesyrederivater, deres fremstilling og anvendelse som herbicider
NO890328L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 4-amino-2,3-disubstituert-6,7-dihydro-5h-1-pyrindinderivater.
ZA894093B (en) Substituted 4-(quinolin-2-yl-methoxy)pehnyl-acetic acid derivatives
DK231489D0 (da) Azacykliske carboxylsyrederivater, deres fremstilling og anvendelse
FI971012A (fi) 1,4-dihydro-4-okso-3-kinoliinikarboksyylihappojohdannaiset ja niiden käyttö

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired